Substantial Investment in Analytical Equipment and Impairment Risk
First written in FY2018. 16 of 21 entries say "Materialised", first in FY2020-Q1. Latest entry: FY2026.
OncoTherapy Science moved to the "Worse" side of this theme in 2019, 5 years before the typical company in this theme (2024).
The whole theme swung hardest in 2026: 19 of 24 companies on the "Worse" side.
4 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥63.216 million.」
The Group recognized an impairment loss of ¥63.216 million on tools, furniture and fixtures and other assets relating to the cancer precision medicine business. The amount increased substantially from ¥0.279 million in the previous fiscal year, and impairment associated with capital investment expanded. - FY2026-H1MaterialisedAnnual report
「During the current interim consolidated fiscal period, the Group recognized an impairment loss of ¥60.967 million.」
The Group recognized an impairment loss of ¥60.967 million during the current interim consolidated fiscal period, and impairment associated with capital investments and other assets continued to actually occur. - FY2025MitigatedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥0.279 million.」
Impairment losses fell substantially from ¥154.564 million in the previous fiscal year to ¥0.279 million. However, impairment associated with capital investment in the cancer precision medicine business continued to occur. - FY2024MaterialisedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥154.564 million.」
The Group recognized an impairment loss of ¥154.564 million on tools, furniture and fixtures relating to the cancer precision medicine business. The impairment risk associated with capital investment actually materialized at a substantial amount. - FY2024-Q3MaterialisedAnnual report
「During the first quarter of the current consolidated fiscal year, the Group recognized an impairment loss of ¥2.627 million relating to the cancer precision medicine business.」
An impairment loss of ¥2.627 million relating to the cancer precision medicine business was recognized, increasing from ¥0.751 million in the same period of the previous fiscal year. Impairment associated with capital investments and other assets continues to occur. - FY2024-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated fiscal year, the Group recognized an impairment loss of ¥2.627 million relating to the cancer precision medicine business.」
An impairment loss relating to the cancer precision medicine business was actually recognized, increasing from ¥0.751 million in the same period of the previous fiscal year to ¥2.627 million. Impairment associated with investment in analytical equipment and other assets continues to occur. - FY2023MitigatedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥21.553 million.」
Impairment losses fell substantially from ¥547.773 million in the previous fiscal year to ¥21.553 million. However, impairment losses continued to occur in the pharmaceuticals research and development business, the cancer precision medicine business and corporate assets. - FY2023-Q3MaterialisedAnnual report
「During the first nine months of the current consolidated fiscal year, the Group recognized an impairment loss of ¥0.151 million relating to the pharmaceuticals research and development business and related businesses, an impairment loss of ¥0.975 million relating to the cancer precision medicine business, and an impairment loss of ¥19.272 million on corporate assets not attributable to a reportable segment.」
The Group recognized total impairment losses of ¥20.398 million during the first nine months, with impairment actually occurring in the cancer precision medicine business, the pharmaceuticals research and development business, and corporate assets. - FY2023-Q2MaterialisedAnnual report
「During the first six months of the current consolidated fiscal year, the Group recognized an impairment loss of ¥0.975 million relating to the cancer precision medicine business and an impairment loss of ¥5.966 million on corporate assets not attributable to a reportable segment.」
The Group recognized total impairment losses of ¥6.941 million during the quarter, and impairment actually occurred in the cancer precision medicine business and corporate assets. - FY2023-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated fiscal year, the Group recognized an impairment loss of ¥0.751 million relating to the cancer precision medicine business.」
An impairment loss of ¥0.751 million relating to the cancer precision medicine business was recognized, and the impairment risk associated with investment in analytical equipment and other assets continues to materialize. - FY2022MaterialisedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥547.773 million.」
The impairment loss increased to ¥547.773 million for the full year. The Group recognized ¥467.740 million in the cancer precision medicine business, ¥50.183 million in the pharmaceuticals research and development business, and ¥29.850 million in corporate and eliminations, with impairment associated with investment in analytical equipment and other assets continuing to occur. - FY2022-Q3MaterialisedAnnual report
「During the first nine months of the current consolidated fiscal year, the Group recognized an impairment loss of ¥465.428 million relating to the cancer precision medicine business.」
An impairment loss of ¥465.428 million relating to the cancer precision medicine business was recognized. The impairment risk associated with investment in analytical equipment and other assets actually materialized, and the cumulative amount increased from the previously disclosed ¥324.781 million. - FY2022-Q2MaterialisedAnnual report
「During the first six months of the current consolidated fiscal year, the Group recognized an impairment loss of ¥324.781 million relating to the cancer precision medicine business.」
An impairment loss of ¥324.781 million relating to the cancer precision medicine business was recognized. The impairment risk associated with investment in analytical equipment and other assets, which had previously been disclosed at ¥9.740 million, expanded significantly and actually materialized. - FY2022-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated fiscal year, the Group recognized an impairment loss of ¥11.036 million relating to the cancer precision medicine business.」
An impairment loss of ¥11.036 million relating to the cancer precision medicine business was actually recognized, and the impairment risk associated with investment in analytical equipment and other assets continues to materialize. - FY2021-Q3MaterialisedAnnual report
「During the first nine months of the current consolidated fiscal year, the Group recognized an impairment loss of ¥9.878 million relating to the cancer precision medicine business.」
An impairment loss of ¥9.878 million relating to the cancer precision medicine business was actually recognized, and the impairment risk associated with investment in analytical equipment and other assets has materialized. - FY2021-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated fiscal year, the Group recognized an impairment loss of ¥9.740 million relating to the cancer precision medicine business.」
An impairment loss of ¥9.740 million on property, plant and equipment relating to the cancer precision medicine business was actually recognized, and the impairment risk associated with investment in analytical equipment and other assets materialized again. - FY2020-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated fiscal year, the Group recognized an impairment loss of ¥162.168 million relating to the cancer precision medicine business.」
An impairment loss of ¥162.168 million on property, plant and equipment relating to the cancer precision medicine business was actually recognized, making the impairment risk associated with investment in analytical equipment and other assets a reality. - FY2018First statedAnnual report
「These capital investments may be substantial. If the value of the assets declines or expected future cash flows can no longer be anticipated, impairment charges may be required, potentially adversely affecting the Group's operating results and financial position.」
The Group newly disclosed the risk of impairment resulting from increased investment amounts and failure to achieve projected future cash flows in connection with proactive investment in research and development and testing equipment.